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ABSTRACT 
Background and aims: Immunosuppressive regimens are a key component for 
successful kidney transplantation. This systematic review aimed to assess the efficacy 
and safety of combination therapy of everolimus with tacrolimus in kidney 
transplantation recipients. 
Methods: Results were limited to English-language articles. Trials where recipients 
received another regimen were excluded. The Cochrane Central Register of Controlled 
Trials and MEDLINE were searched via the optimally sensitive strategies for the 
identification of randomized trials, combined with the following MeSH headings and text 
words: Everolimus, Certican, Zortress, tacrolimus, prograf, and kidney transplantation. 
Results: Five relevant studies of everolimus in combination with tacrolimus were 
identified and results of them were interpreted. Two trials investigated Fix dose of 
everolimus in combination with low (1.5-3 mg) versus standard dose of tacrolimus  
(4-7 mg). One trial investigated variable doses of everolimus (1.5 mg/day or 3 mg/day) in 
combination with fix dose of tacrolimusand two trials compared fix dose of everolimus 
versus reduction or elimination of tacrolimus. Sample size of RCTs ranged from 20 to 
398 and the follow up time ranged from six to 24 months. The quality score on the Jadad 
score was 3 in all five trials indicating moderate quality. 
Conclusion: Immune suppressive regimens including everolimus in combination with 
tacrolimus therapy show better safety and efficacy compared with single-mode but these 
differences were not significant in overall studies. In general, compared with a regimen 
without combination of everolimus with tacrolimus, the newer immunosuppressive 
regimen consistently reduced the incidence of short-term biopsy-proven acute rejection. 
However, evidence about impact on side-effects, long term graft loss, compliance and 
overall health-related quality of life is limited. 
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INTRODUCTION 
The occurrence of end-stage kidney 
disease is estimated to have reached 
1,900,000 people worldwide, of whom 
1,455,000 go through dialysis treatment, and 
the remaining 455,000 are living with a 
functioning renal allograft. The global rise 
in the number of patients with chronic 
kidney disease (CKD) and consequent end-
stage renal disease (ESRD)necessitate renal 
replacement therapy is threatening to reach 
epidemic proportions over the next  
decade.
1-3
 Kidney transplant recipients have 
better rates of mortality when compared 
with the general population. The new 
immunosuppressive drugs have enhanced 
short-term patient survival up to 95% at  
1-2 years, but these data have to be 
confirmed in long-term follow-up. 
Additionally, no particular regime has 
proved to be superior over others with 
regard to patient survival.
4,5
 
Kidney transplantation is the most 
excellent treatment for patients with ESRD. 
Data from registries have shown that a 
functioning kidney improves patient survival 
at what time compared with patients 
enrolled on waiting lists, even after 
adjusting for age, sex, primary renal disease 
and co-morbidities.
6
 From early 70s to late 
80s, totally patient survival improved by at 
least 8% at each of 1, 5 and 10 years  
post-transplant, and by the late 1990s overall 
survival with functioning graft at 10 years 
had reached 86%.
7,8
 However, life 
expectancy in the general population is more 
than renal transplant recipients, and this has 
been attributed to increased mortality rates 
because of cardiovascular diseases, 
infections and likewise malignancies.
9
 
Prevention of acute rejection was the 
main purpose of immunosuppressive 
maintenance therapy. However, efforts have 
been directed to prevent and control the 
onset of chronic transplant nephropathy and 
calcineurin toxicity, two of the main causes 
of long-term graft loss.The advent of a new 
type of agents-proliferation signal inhibitors 
(PSI): Such sirolimus and everolimus)  
offers an option to agents that block 
calcineurin. Additionally, PSI is the only 
immunosuppressive medications that seem 
to diminish the incidence of malignancy.
10,11 
Mammalian target of rapamycin inhibitors 
characterize a new, promising therapeutic 
group of immunosuppressive drugs for 
kidney transplantation. sirolimus first, and 
recently everolimus, have been merged to 
clinical practice.
12
 
Mammalian target of rapamycin 
Inhibitors have been increasingly proposed 
as alternative immunosuppressive agents in 
renal transplantation because of their 
inimitable mechanism of action and 
apparently favorable side effect profile.
13,14
 
Everolimus (EVL) was approved for clinical 
use in Europe in 2005 for the indication of 
use in de novo renal transplant patients 
combined with low dose cyclosporine.
15
 One 
option that has been studied to conserve 
renal function and reduce the risk of cardio-
vascular adverse events (AEs) is combining 
an m-TOR inhibitor (everolimus) with 
tacrolimus for organ transplant recipients.
10
 
The aims of this review, was to discuss 
about the safety and efficacy of combination 
therapy with everolimus and tacrolimus in 
kidney transplant. 
 
METHODS 
All randomized controlled trials where 
drug regimens contained everolimus in 
combination with tacrolimus were compared 
with an alternative drug regimen when 
treating recipients of a first or subsequent 
kidney transplant in the post-transplant 
period were included. There was no 
restriction by age of recipients, or dosage of 
immunosuppressive drugs. Results were 
limited to English language articles. Trials 
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where recipients received another regimen 
were excluded. The Cochrane Central 
Register of Controlled Trials and MEDLINE 
was searched via the optimally sensitive 
strategies for the identification of randomized 
trials, combined with the following MeSH 
headings and text words: everolimus, 
certican, zortress, tacrolimus, prograf, and 
kidney transplantation. Outcomes assessed 
were mortality, graft loss, acute rejection, 
graft function (any measure of creatinine or 
measured or calculated glomerular filtration 
rate), infection (including symptomatic 
cytomegalovirus infection), malignancies, 
and a variety of treatment-related adverse 
reactions.The study quality was assessed by 
two reviewers independently, and any 
disagreements were resolved by consensus. 
RCTs were appraised using the JADAD 
scale(is a procedure to independently assess 
the methodological quality of a clinical trial 
using three items include; randomization, 
blinding, withdrawals and dropouts).To 
assess heterogeneity I2 and P were used 
(Values between 0% and 25% indicated that 
heterogeneity might not be important. Values 
between 25% and 50% indicated moderate 
inconsistency. Values of 50% to 75%  
were indicated substantial heterogeneity. 
Values between 75% and 100% indicated 
considerable inconsistency and p<0.05 
indicated high heterogeneity). 
 
RESULTS 
In general, five studies were included in 
these review and all of them were 
randomized clinical trial.
16-20
 The main 
features of the final studies are summarized 
in Table 1. 
 
Table 1: Main characteristics of included studies 
Study Publication 
year 
Study 
design 
Number of 
samples 
Duration of 
follow up 
Arm of study 
Intervention Group Comparison Group 
Chan, et al. 2008 RCT 92 6 month 1.5 mg EVL+ Low TAC 
(1.5-3 mg) 
1.5 mg EVL + Standard 
TAC (4-7 mg) 
Cataneo-davila, et al. 2009 RCT 20 12 month EVL+CNI withdrawal EVL+CNI reduction 
Pascual, at al. 2010 RCT 35 6 month 1.5 mg/day EVL+TAC 3 mg/day EVL+TAC 
Holdaas, et al. 2011 RCT 398 24 month EVL+CNI minimization EVL+CNI unchanged 
EVL+CNI elimination 
Langer, et al. 2012 RCT 228 12 month EVL+TAC (1.5-3 ng/ml) EVL+TAC (4-7 ng/ml) 
EVL: everolimus; TAC: tacrolimus; RCT: randomized clinical trial; CNI: calcineurin inhibitor 
 
All Five trials have compared different 
doses of everolimus in combination with 
tacrolimus. Two trials investigated fixed 
dose of everolimus in combination with low 
(1.5-3 mg/kg) versus standard dose of 
tacrolimus (4-7 mg/kg).
16,19
 One trial 
investigated variable doses of everolimus 
(1.5 mg/day or 3 mg/day) in combination 
with fixed dose of tacrolimus and two trials 
compared fixed dose of everolimus versus 
reduction or elimination of tacrolimus.
17,18,20
 
Most of these trials had two arms, but one 
trial had three arms and also compared fixed 
dose of everolimus in combination with 
tacrolimus minimization or elimination 
versus fixed dose of everolimus with 
unchanged dose of tacrolimus.
18
 High 
number outcomes were not reported by all 
trials or if reported, no comprehensible 
definitions were provided. For example,  
four trials reported serum creatinine, four 
trials reported GFR (eGFR or mGFR), and 
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two trials reported creatinine clearance.
16-20
 
Age of participant was different in trials 
(from 18-65 years, mean age was 46.7). In 
all, we identified five randomized controlled 
trials involving 773 patients. Sample size of 
RCTs ranged from 20 to 398 and the follow 
up time ranged from six to 24 months.The 
quality score on the Jadad score was 3 in all 
five trials indicating moderate quality. All 
five studies were published as full Journal 
articles. 
All five trials reported mortality.In three 
of the five studies, no deaths occurred in the 
study groups.
16,17,20
 In one study, three deaths 
occurred in the tacrolimus elimination group, 
all with no suspected relation to study drug, 
and there were three deaths in the tacrolimus 
minimization group, one suspected to be 
related to study drug and no deaths occurred 
in the control group.
18
 In one study, three 
deaths occurred in each of the study groups.
19
 
In all five studies there was no significant 
difference in mortality between the 
groups.The main causes of death in different 
studies were cytomegalovirus infection, viral 
encephalitis, hemolytic uremic syndrome and 
invasive as pergillosis. 
In four studies of all included studies 
there was no significant difference in acute 
rejection between the groups.
16-18,20
 One 
study showed significant difference between 
two groups of the study (20 cases in low 
tacrolimus group and 9 cases in standard 
tacrolimus group, P=0.0138).
19
 Chan et al 
reported that 13 Biopsy-proven acute 
rejection (BPAR) occurred in 13 patients: 
seven in the low tacrolimus group (14%) 
and six in the standard tacrolimus group 
(14%) (P=0.872).
16
 Cataneo-davila et al 
reported that one patient in the tacrolimus 
reduction group experienced an acute 
rejection episode (Banff grade Ib), and two 
patients in tacrolimus reduction group and 
one patient in tacrolimus withdrawal group 
demonstrated borderline changes, all related 
to everolimus blood concentration less than 
3 ng/mL.
17
 In one study, three acute 
rejections occurred in each of the study 
groups; Acute rejection incidence rate was 
similar in both groups: 3(20%) for low 
everolimus group (A) and 3(15%) for high 
everolimus group (B). Acute rejections in 
group A were IA (n_1), IB (n_1), and IIB 
(n_1), whereas in group B, they were IA 
(n_1), IB (n_1), and antibody-mediated 
rejection (n_1).
20
 Holdaas et al reported  
7 BPAR in tacrolimus elimination group,  
8 BPAR in tacrolimus minimization group 
and 3 BPAR in everolimus unchanged 
group, all differences were not significant.
18
 
In four studies of all included studies 
there was no significant difference in acute 
rejection rate between the groups.
16-18,20
  
One study showed significant difference 
between two groups of the study.
19
 In one 
study no graft loss was registered in each of 
the study groups.
17
 In one study, one graft loss 
occurred in the standard tacrolimus group and 
no graft loss occurred in low tacrolimus 
group.
16
 One study reported one graft loss, but 
it is not mentioned in which group it 
occurred.
20
 Holdaas et al reported 8 graft 
losses in tacrolimus minimization group, 4 in 
tacrolimus elimination group and 6 in control 
group, differences between groups were of no 
significant.
18
 Langer et al reported 8 graft 
losses in low tacrolimus group and 2 graft 
losses in standard tacrolimus group, this 
difference was significant between two groups 
of study.
19
 Overall mean graft loss was 0-7% 
in these studies. The main reasons for  
graft loss were: Thrombotic microangiopathy, 
necrosis, kidney bleeding with  
possible infected arterial anastomoses, 
immunosuppression withdrawal, and technical 
issues and acute rejection. 
Renal function has been reported in 
several studies by various indices, including 
serum creatinine (sCr), creatinine clearance 
(CrCl) and glomerular filtration rate (GFR). 
There was no significant difference in renal 
function between all included studies. In Chan 
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et al Mean serum creatinine at six months was 
118±41 mol/L (1.33±0.46 mg/dL) for the 
whole study population, and 112±31 mol/L 
(1.26±0.35 mg/dL) and 127±50 mol/L 
(1.44±0.57 mg/dL) in the low and standard 
tacrolimus groups, respectively. Estimated 
GFR(Nankivel) and creatinine clearance for 
the total study population at six months were 
both very well preserved (mean GFR 
69.0±22.3 mL/min; mean creatinine clearance 
75.2±27.9 mL/min) and there were no 
significant differences amongtwo treatment 
groups.
16
 Cataneo-davila et al reported that at 
12 months after conversion to everolimus 
therapy, no significant difference among 
baseline concentrations and those at month 12 
for both Scr and eGFR was observed in each 
study group. At baseline and at 12 months, Scr 
and eGFR concentrations in group one were 
1.27±0.35 mg/dL vs 1.24±0.4 mg/dL (not 
signiﬁcant) and 72.4±19.8 mL/min vs 
76.2±22.6 mL/min (not signiﬁcant), 
respectively, and in group 2 were 1.27±0.36 
mg/dL vs 1.25±0.3 mg/dL (not signiﬁcant) 
and 66.2±12.9 mL/min vs 66.2±13.7 mL/min 
(not signiﬁcant), respectively.17 In Langer et al 
study, At Month 12, mean eGFR was higher 
in the tacrolimus 1.5–3 ng/ml group versus the 
4–7 ng/ml group (57.1±19.5 vs. 51.7±20 
ml/min/1.73 m2, respectively; treatment 
difference: 5.3 ml/min/1.73 m2; 95%  
CI: -0.2, 10.9) although statistical signiﬁcance 
was not observed (P=0.0299) at the level of 
0.025. A post-hocANOVA of the eGFR 
(MDRD) difference at Month 12 adjusting for 
the eGFR (MDRD) value at Month 3 (start of 
different treatment regimens) as a sensitivity 
analysis yielded similar results  
(P=0.0445).
19
 In Holdaas et al study, renal 
function measured with GFR was stable in all 
groups to month 24.
18
 
Differences in adverse events between 
treatment groups were not statistically 
significant in all studies.The main adverse 
events of interest to clinicians included 
hypertension, diabetes mellitus, and 
malignancies. The most frequent serious 
adverse events were urinary tract 
infection.
16,18-20
 Then, edema, peripheral 
edema, and anemia were the most frequently 
reported in the literature.Adverse events with a 
suspected relation to everolimus were reported 
in 30 patients and 24 patients in the low and 
standard tacrolimus groups, respectively.
16
 
One study reported there was no opportunistic 
viral or bacterial infection which could be 
assessed as a serious adverse event.
17
 Other 
adverse events reported in all studies included; 
hypercholesterolemia, dyslipidemia, 
hyperlipidemia, hypokalemia, diabetes 
mellitus, hypertriglyceridemia, diarrhea, 
constipation, pyrexia, procedural pain, 
hypertension, Lymphocele, proteinuria, acne, 
headache and insomnia. 
 
CONCLUSION 
Clinical trials have confirmed that the 
everolimus, in combination with low dose 
tacrolimus, is effective in preventing 
rejection episodes and graft loss. We 
identified a total of 5 relevant studies in 
literature that specifically evaluated 
combination therapy of everolimus with 
tacrolimus in kidney transplant recipients. 
773 patients participated in these studies. 
Results of the present study do not enable us 
to make any favorable statement about the 
use of CNI elimination rather than CNI 
reduction to preserve graft function.Our 
review suggests that immunosuppressive 
regimens including everolimus in 
combination with tacrolimus therapy show 
better safety and efficacy compared with 
single-mode, but these differences are not 
significant in overall studies. In general, 
compared with a regimen without 
combination of everolimus with tacrolimus, 
the newer immunosuppressive regimen 
consistently reduced the incidence of  
short-term biopsy-proven acute rejection. 
However, evidence of the impact on  
Arab Zozani M, et al. Combination therapy with everolimus 
89 
side-effects, long term graft loss, 
compliance and overall health-related 
quality of life is limited. Differences 
between the various modes of combination 
therapy (include reduction, elimination or 
fix dose of each drug) are generally not 
significant in the included studies. 
Everolimus was also associated with the 
lowest incidence of dyslipidemia, new-onset 
diabetes mellitus (NODM), and wound 
healing postponement in kidney transplant 
recipients receiving reduced tacrolimus. 
Data about combination therapy of 
everolimus with tacrolimus are much less in 
kidney transplantation, but evidence to date 
suggests combination therapy in kidney 
transplant recipients. Long-term hard 
endpoint data from methodologically robust 
randomized trials are still required. 
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